Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
NK cell infusions induce complete remissions in 30–50% of patients with refractory AML when combined with lymphodepleting chemotherapy and IL-2. NK cell therapy is limited by lack of antigen specificity and by IL-2 mediated induction of Tregs. To overcome these limitations we developed a 161533 trispecific killer engager (TriKE) molecule containing an anti-CD16 scFv, to engage NK cells, an anti-CD33 scFv, to engage AML targets, and an IL-15 molecule.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.